Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon's breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to injections ...

Approved for use by diabetics to control blood sugar, liraglutide has also evidenced an ability to slow cognitive decline in a Phase 2b clinical trial, and reduce shrinkage of those areas of the brain ...

Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon’s breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to injections ...

Lexaria has already demonstrated success in DehydraTECH processing for superior human oral delivery performance of the world's two most widely used GLP-1 drugs; semaglutide (Novo Nordisk®) and ...

Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon's breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to ...

The study will test an oral version of liraglutide ... promising results in enhancing the bio-absorption of several GLP-1 drugs, including liraglutide, semaglutide, and tirzepatide, which are ...

GLP-1 drugs, which stands for glucagon-like peptide ... with the program selling oral weight-loss medications for about $79 ...

It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor ... trials of an oral formulation of ...

Some analysts have predicted Rybelsus could eventually become a $5 billion product, once clinicians become accustomed to having an oral alternative to the current injectable GLP-1 drugs.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.